Literature DB >> 15567876

Can we eliminate severe ovarian hyperstimulation syndrome?

Raoul Orvieto1.   

Abstract

The desire of some couples for children is so strong that they are willing to accept a modicum of risk to treat their infertility. Ideally, assisted reproduction technology practitioners seek a balance between optimum ovarian stimulation and successful treatment outcome with minimal rate of severe ovarian hyperstimulation syndrome (OHSS) or multiple pregnancies. However, despite many years of clinical experience, there are no precise methods to completely prevent severe OHSS, except by withholding the ovulation-inducing trigger of hCG. Individualization of treatment according to the specific risk factor and the specific response in the current cycle with the option of freezing of all embryos, or replacement of only a single embryo, has the potential of reducing the risk and the severity of the syndrome in susceptible cases. We offer a triage aimed at eliminating the occurrence of severe ovarian hyperstimulation syndrome on the basis of several clinical observations, including the role of GnRH antagonist in controlled ovarian stimulation protocols, the option of freezing of all embryos, or replacement of only a single embryo in the blastocyst stage.

Entities:  

Mesh:

Year:  2004        PMID: 15567876     DOI: 10.1093/humrep/deh613

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  20 in total

1.  Prevention of ovarian hyperstimulation syndrome by early aspiration of small follicles in hyper-responsive patients with polycystic ovaries during assisted reproductive treatment cycles.

Authors:  Oluseye A Oyawoye; Bina Chander; Jocelyn Hunter; Ahmed Abdel Gadir
Journal:  MedGenMed       Date:  2005-08-16

2.  Anaesthetic Issues in In-vitro Fertilisation.

Authors:  Tvsp Murthy; P Gupta; R K Sharma
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2015-08-21       Impact factor: 4.234

4.  GnRH antagonist for patients with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer in fresh cycles.

Authors:  Xiang-Hong Zhai; Ping Zhang; Feng-Xia Wu; An-Cong Wang; Pei-Shu Liu
Journal:  Exp Ther Med       Date:  2017-04-05       Impact factor: 2.447

5.  Ovarian hyperstimulation syndrome following GnRH agonist trigger-think ectopic.

Authors:  Raoul Orvieto; Valeria Stella Vanni
Journal:  J Assist Reprod Genet       Date:  2017-06-09       Impact factor: 3.412

Review 6.  The myths surrounding mild stimulation in vitro fertilization (IVF).

Authors:  Raoul Orvieto; Valeria Stella Vanni; Norbert Gleicher
Journal:  Reprod Biol Endocrinol       Date:  2017-06-24       Impact factor: 5.211

7.  A matched propensity score study of embryo morphokinetics following gonadotropin-releasing hormone agonist versus human chorionic gonadotropin trigger.

Authors:  Galia Oron; Onit Sapir; Avital Wertheimer; Yoel Shufaro; Roni Bar-Gil; Tamar Margalit; Ekaterina Shlush; Avi Ben-Haroush
Journal:  J Assist Reprod Genet       Date:  2020-09-27       Impact factor: 3.412

8.  Severe ovarian hyperstimulation syndrome in a 42-year-old woman with successful pregnancy after intracytoplasmic sperm injection embryo transfer.

Authors:  Hiroaki Shibahara; Kazuhiko Shimada; Yukako Morimatsu; Kumiko Kikuchi; Yuki Hirano; Tatsuya Suzuki; Satoru Takamizawa; Mitsuaki Suzuki
Journal:  Reprod Med Biol       Date:  2005-11-02

9.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.